JP2023500033A - 血管新生性眼疾患を治療又は予防するためのカルレティキュリン - Google Patents

血管新生性眼疾患を治療又は予防するためのカルレティキュリン Download PDF

Info

Publication number
JP2023500033A
JP2023500033A JP2022521196A JP2022521196A JP2023500033A JP 2023500033 A JP2023500033 A JP 2023500033A JP 2022521196 A JP2022521196 A JP 2022521196A JP 2022521196 A JP2022521196 A JP 2022521196A JP 2023500033 A JP2023500033 A JP 2023500033A
Authority
JP
Japan
Prior art keywords
calreticulin
pharmaceutical composition
crt
eye
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022521196A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500033A5 (OSRAM
Inventor
リマンタス・スリビンスカス
エヴァルダス・チプリス
Original Assignee
ユーエービー バルティマス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーエービー バルティマス filed Critical ユーエービー バルティマス
Publication of JP2023500033A publication Critical patent/JP2023500033A/ja
Publication of JP2023500033A5 publication Critical patent/JP2023500033A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1738—Calcium binding proteins, e.g. calmodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2022521196A 2019-10-08 2020-10-07 血管新生性眼疾患を治療又は予防するためのカルレティキュリン Pending JP2023500033A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201914516A GB201914516D0 (en) 2019-10-08 2019-10-08 Treatment of eye disease
GB1914516.8 2019-10-08
PCT/EP2020/078173 WO2021069523A1 (en) 2019-10-08 2020-10-07 Calreticulin for treating or preventing an angiogenic eye disease

Publications (2)

Publication Number Publication Date
JP2023500033A true JP2023500033A (ja) 2023-01-04
JP2023500033A5 JP2023500033A5 (OSRAM) 2023-11-29

Family

ID=68541456

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022521196A Pending JP2023500033A (ja) 2019-10-08 2020-10-07 血管新生性眼疾患を治療又は予防するためのカルレティキュリン

Country Status (6)

Country Link
US (1) US20220370554A1 (OSRAM)
EP (1) EP4041280A1 (OSRAM)
JP (1) JP2023500033A (OSRAM)
KR (1) KR20220079917A (OSRAM)
GB (1) GB201914516D0 (OSRAM)
WO (1) WO2021069523A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114699506A (zh) * 2021-12-30 2022-07-05 北京百华百汇生物科技有限公司 重组钙网蛋白在生发、育发、保护毛发或防脱发中的用途和相关产品

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867180B1 (en) 1998-10-06 2005-03-15 The United States Of America As Represented By The Department Of Health And Human Services Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth
AU6291799A (en) 1998-10-06 2000-04-26 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth
US9254310B2 (en) * 2010-06-17 2016-02-09 New York University Therapeutic and cosmetic uses and applications of calreticulin
TWI445543B (zh) 2012-05-03 2014-07-21 Univ Nat Sun Yat Sen 一種用以治療眼部脈絡膜血管新生之醫藥組合物
EP2872644B1 (en) 2012-07-12 2017-07-12 UAB Baltymas Generation of native recombinant secreted human endoplasmic reticulum chaperones by using their native signal sequences in yeast expression systems
GB201401453D0 (en) * 2014-01-28 2014-03-12 Univ Birmingham Transmucosal and transepithelial drug delivery system

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BEE, Y. S. ET AL.: "Inhibition of Experimental Choroidal Neovascularization by a Novel Peptide Derived from Calreticulin", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 19, no. 10, JPN6024043261, 2018, pages 2993, ISSN: 0005447668 *
LIU, X. ET AL.: "Adenovirus-mediated delivery of CALR and MAGE-A3 inhibits invasion and angiogenesis of glioblastoma", JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol. 31, no. 1, JPN6024043256, 2012, pages 8, XP021124117, ISSN: 0005603340, DOI: 10.1186/1756-9966-31-8 *
TU, L. ET AL.: "AAV-mediated gene delivery of the calreticulin anti-angiogenic domain inhibits ocular neovasculariza", ANGIOGENESIS, vol. 21, no. 1, JPN6024043259, 2018, pages 95 - 109, XP036430300, ISSN: 0005447669, DOI: 10.1007/s10456-017-9591-4 *
中村 忠博，佐々木 均: "点眼剤の基本設計", 薬局, vol. 第65巻，第5号, JPN6024043258, 2014, pages 1717 - 1722, ISSN: 0005603343 *
佐藤 靖史: "血管新生研究の進歩と展望", 血管医学, vol. 第11巻，第3号, JPN6024043257, 2010, pages 211 - 217, ISSN: 0005603341 *
医薬品安全性情報 [ONLINE], vol. No.11, No.02, JPN6024043260, 17 January 2013 (2013-01-17), ISSN: 0005603342 *

Also Published As

Publication number Publication date
KR20220079917A (ko) 2022-06-14
US20220370554A1 (en) 2022-11-24
GB201914516D0 (en) 2019-11-20
WO2021069523A1 (en) 2021-04-15
EP4041280A1 (en) 2022-08-17

Similar Documents

Publication Publication Date Title
Wang et al. A thermo-responsive protein treatment for dry eyes
CN100577202C (zh) 药理玻璃体溶解术
Giannaccare et al. Anti-VEGF treatment in corneal diseases
Wilkinson-Berka et al. Update on the treatment of diabetic retinopathy
AU2014346051B2 (en) Use of IL-22 dimers in manufacture of medicaments for treating pancreatitis
AU2021286438B2 (en) Compositions and methods for prevention and treatment of corneal haze and scarring
KR20220027266A (ko) Adamts13의 피하 투여
CA2955481A1 (en) Collagen iv replacement
CA2666843C (en) Treatment of age-related macular degeneration and other diseases of the eye
JP7068706B2 (ja) 網膜神経変性疾患の眼局所治療のためのジペプチジルペプチダーゼ－４阻害剤
WO2014203181A1 (en) Treatment of polypoidal choroidal vasculopathy
JP7650074B2 (ja) 眼疾患を治療するための組成物及び方法
US20220370554A1 (en) Calreticulin for Treating or Preventing an Angiogenic Eye Disease
JP6944463B2 (ja) 眼疾患の治療のための組成物及び方法
del Valle Cano et al. A Peptide Derived from Type 1 Thrombospondin Repeat–Containing Protein WISP-1 Inhibits Corneal and Choroidal Neovascularization
CN115942951A (zh) Ngf变体，制备，组合物和治疗用途
WO2022125548A1 (en) Growth and differentiation factor 15 for treatment of proliferative vitreoretinopathy therapy
Casati et al. Sustained regression of florid diabetic retinopathy in a patient with Donohue syndrome (leprechaunism)
El-Asrar et al. Advances in the treatment of diabetic retinopathy
CN105017406B (zh) 一类新的具有神经保护功能的多肽
US9266933B2 (en) Polypeptides inhibiting neovascularization and uses thereof
JP2023500033A5 (OSRAM)
RU2860337C2 (ru) Офтальмологическая фармацевтическая композиция и ее применение
CN117100845A (zh) 重组人奥克纤溶酶在制备治疗脉络膜血管疾病药物中的用途
US20250000936A1 (en) Treatment of geographic atrophy

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20221219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231117

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250325

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250527